Stockscreener 앱 받기
72.13
3.97%
-2.98
시간 외 거래:
72.13
전일 마감가:
$75.11
열려 있는:
$75.18
하루 거래량:
2.87M
Relative Volume:
1.29
시가총액:
$8.48B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
23.88
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
+7.18%
1개월 성능:
+14.71%
6개월 성능:
+29.27%
1년 성능:
+34.17%
1일 변동 폭
$72.06
$75.51
1주일 범위
$67.16
$75.59
52주 변동 폭
$47.50
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
72.13 | 8.83B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-10-14 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
How supply chain issues affect Halozyme Therapeutics Inc. stockPortfolio Risk Report & Consistent Profit Alerts - ulpravda.ru
Will Halozyme Therapeutics Inc. stock see insider buyingDividend Hike & Verified Technical Signals - ulpravda.ru
Is Halozyme Therapeutics Inc. stock ready for breakout2025 Key Highlights & Growth Focused Entry Reports - ulpravda.ru
Can Halozyme Therapeutics Inc. stock surprise with earnings upsideQuarterly Profit Review & Daily Momentum Trading Reports - ulpravda.ru
TD Cowen Raises Price Target for HALO to $90.00, Maintains Buy Rating | HALO Stock News - GuruFocus
TD Cowen raises Halozyme Therapeutics stock price target to $90 on growth outlook - Investing.com Canada
Halozyme Partners with Takeda to Develop and Commercialize Vedolizumab - Contract Pharma
Halozyme Allows Takeda To Access Its ENHANZE Drug Delivery Technology For Use With Vedolizumab - Nasdaq
Takeda (TAK) Partners with Halozyme for Enhanced Drug Delivery - GuruFocus
Halozyme signs licensing deal with Takeda for vedolizumab delivery tech By Investing.com - Investing.com Australia
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE - Chartmill
Why Halozyme Therapeutics Inc. stock remains undervaluedLarge Cap Stability Picks & Low Cost Capital Trading - ulpravda.ru
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience - Yahoo Finance
Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings? - Finviz
Insider Sell: Bernadette Connaughton Sells 2,000 Shares of Halozyme Therapeutics Inc (HALO) - GuruFocus
Is Halozyme Therapeutics Inc. (RV7) stock undervalued after correction2026 world cup usa national team round of 16 goalkeepers high defensive line knockout prediction expert opinion - ulpravda.ru
Halozyme and Skye partner on obesity drug delivery technology By Investing.com - Investing.com Nigeria
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Halozyme Therapeutics, Skye Bioscience Collaborate to Evaluate Nimacimab for Obesity Treatment - MarketScreener
Skye Bioscience Licenses Halozyme’s ENHANZE Drug Delivery Technology - Contract Pharma
Skye Bioscience stock jumps after Halozyme collaboration for obesity drug By Investing.com - Investing.com Nigeria
Skye Bioscience stock jumps after Halozyme collaboration for obesity drug - Investing.com
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Robust Revenue Growth and Strategic Partnerships Fuel Investor Optimism - DirectorsTalk Interviews
Halozyme Therapeutics (HALO) Partners with Skye Bioscience for I - GuruFocus
Halozyme (HALO) Partners with Skye Bioscience for Obesity Treatm - GuruFocus
Halozyme and Skye partner on obesity drug delivery technology - Investing.com
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity - The Manila Times
Halozyme Therapeutics (FRA:RV7) EV-to-OCF : 14.00 (As of Jan. 04, 2026) - GuruFocus
Cwm LLC Acquires 22,813 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Arbor Investment Advisors LLC Invests $1.32 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Valuation Update: Why Halozyme Therapeutics Inc RV7 stock is a must watch tickerJuly 2025 Rallies & Low Drawdown Trading Techniques - moha.gov.vn
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 - The Globe and Mail
How Halozyme Therapeutics Inc. (HALO) Affects Rotational Strategy Timing - Stock Traders Daily
Here's What Analysts Think About Halozyme Therapeutics (HALO) - Finviz
Here’s What Analysts Think About Halozyme Therapeutics (HALO) - Insider Monkey
Market Still Lacking Some Conviction On Halozyme Therapeutics, Inc. (NASDAQ:HALO) - 富途牛牛
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Hold" by Brokerages - MarketBeat
Zacks Research Brokers Increase Earnings Estimates for HALO - MarketBeat
Shaker Investments LLC OH Decreases Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Voya Investment Management LLC Has $3.39 Million Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Pacer Advisors Inc. Acquires 456,649 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Osaic Holdings Inc. Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Hedge Fund and Insider Trading News: Steve Cohen, Ray Dalio, Warren Buffett, Alan Howard, Scott Bessent, Saba Capital Management, Halozyme Therapeutics Inc (HALO), Epsilon Energy Ltd (EPSN), and More - Insider Monkey
Halozyme Therapeutics CEO sells $1.14 million in stock - Investing.com
Halozyme Therapeutics Stock Sees Relative Strength Rating - Investor's Business Daily
27,468 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by Monument Capital Management - MarketBeat
Halozyme Therapeutics (HALO): Valuation Check After FDA Win and Patent Court Victory - Yahoo Finance
Halozyme Therapeutics (HALO) Is Up 7.4% After New ENHANZE NSCLC Win And Patent InjunctionWhat's Changed - Yahoo Finance
Is Halozyme Still Attractively Priced After Its Strong 2025 Share Price Rally? - Yahoo Finance
EBITDA per share of Halozyme Therapeutics, Inc. – TRADEGATE:RV7 - TradingView — Track All Markets
Halozyme Therapeutics (BIT:1HALO) Price Target Decreased by 13.37% to 59.51 - Nasdaq
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.80%
4.56%
자본화:
|
볼륨(24시간):